Last reviewed · How we verify
Injection of Secretome-MSCs
At a glance
| Generic name | Injection of Secretome-MSCs |
|---|---|
| Sponsor | Stem Cell and Cancer Research Indonesia |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis (PHASE1, PHASE2)
- Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis (EARLY_PHASE1)
- Skin Rejuvenation Using Stem Cell Secretome (PHASE1)
- Effectiveness of PRP, Conditioned Medium UC-MSCs Secretome and Hyaluronic Acid for the Treatment of Knee Osteoarthritis (PHASE1, PHASE2)
- Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia (PHASE2)
- Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injection of Secretome-MSCs CI brief — competitive landscape report
- Injection of Secretome-MSCs updates RSS · CI watch RSS
- Stem Cell and Cancer Research Indonesia portfolio CI